BPC-157 Injection Resolved Bladder Pain Symptoms in 10 of 12 Women: A Pilot Study

In 12 women with moderate to severe interstitial cystitis who had failed pentosan polysulfate treatment, a single intravesical injection of BPC-157 (10 mg total) around the inflamed bladder area produced complete symptom resolution in 10 of 12 patients (100% success rating). The remaining 2 patients reported 80% improvement. All 12 scored 5/5 on the Global Response Assessment. No adverse events were reported, and no patients dropped out.

This was an open-label pilot study at a private clinic. Twelve women (aged 39-76, mean 58.3 years) with interstitial cystitis who had not responded to pentosan polysulfate underwent cystoscopy. During the procedure, BPC-157 (10 mg total, from a 503A compounding pharmacy) was injected around the area of bladder inflammation in a single treatment. Efficacy was assessed using the Global Response Assessment questionnaire.

Interstitial cystitis (bladder pain syndrome) is a debilitating condition with very limited treatment options — the only approved drug (pentosan polysulfate) often fails and can cause eye damage with long-term use. This pilot study from Dr. Edwin Lee is notable as one of the few published human trials of BPC-157, and the results were striking: a single injection resolved symptoms in most patients who had already failed standard treatment.

BPC-157 has extensive animal data showing tissue-healing properties, but human clinical data has been extremely limited. This is one of the first published human studies of BPC-157 for any condition, and it comes from Dr. Edwin Lee, one of the few physicians publishing human BPC-157 data. If confirmed in controlled trials, intravesical BPC-157 could offer a much-needed alternative for interstitial cystitis patients who don't respond to current treatments.

Very small sample size (12 patients). No placebo control or blinding — this was an open-label study, making placebo effects a significant concern. Single-site study at a private clinic. No long-term follow-up data reported. BPC-157 was sourced from a compounding pharmacy, not pharmaceutical-grade manufacturing. The journal (Alternative Therapies) is not a top-tier urology publication.